Archives 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 May 04, 2022 UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION Read More April 13, 2022 UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More February 07, 2022 LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently Read More January 10, 2022 TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022) Read More January 10, 2022 TR1 – Luca Associates – Major Holdings in Shares (4 January 2022) Read More December 24, 2021 TR1 – Lanstead – Major Holding in Shares Read More December 20, 2021 Subscriptions and Placing to raise £3.55 million; Sharing Agreement; to fund Investment in R&D pipeline • Company’s Partner Alora and two longstanding investors including Lanstead to participate at an Issue price of 11p – 80% premium to current share price Read More November 29, 2021 Collaboration with Imperial College London Read More November 18, 2021 CORPORATE UPDATE – The Evolution of ImmuPharma Read More October 01, 2021 EURONEXT DELISTING – Date: 18 October 2021 Read More September 30, 2021 Prof. Sylviane Muller awarded prestigious Legion d’honneur.’ Read More September 29, 2021 Corporate Update Read More 123…17
April 13, 2022 UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More
February 07, 2022 LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently Read More
December 20, 2021 Subscriptions and Placing to raise £3.55 million; Sharing Agreement; to fund Investment in R&D pipeline • Company’s Partner Alora and two longstanding investors including Lanstead to participate at an Issue price of 11p – 80% premium to current share price Read More
